{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002401","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.322012+00:00","generated_at":"2026-05-23T07:59:07.651744+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arbutus announces five abstracts on imdusiran and AB-101 accepted at EASL 2025, including late-breaker","bullets":["Five abstracts accepted for poster presentation at EASL Congress 2025 (May 7-10, Amsterdam); one late-breaker (LB25153).","Abstract 1768: IM-PROVE I study shows HBsAg at baseline and NA discontinuation associated with functional cure in CHB subjects.","Abstract 2043: Rapid HBV RNA decline during imdusiran lead-in, then transient increases with interferon, linked to HBsAg seroclearance.","AB-101 (oral PD-L1 inhibitor) data: well-tolerated in healthy/subjects, dose-responsive PD-L1 RO, high liver biodistribution.","Late-breaker LB25153: off-treatment antiviral efficacy and safety of repeat imdusiran + VTP-300 with/without nivolumab in CHB."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002401","json":"https://secwatch.observer/filing/0001171843-25-002401.json","markdown":"https://secwatch.observer/filing/0001171843-25-002401.md","text":"https://secwatch.observer/filing/0001171843-25-002401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325002401/0001171843-25-002401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184325002401/f8k_042325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:59:07.651744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}